Events / Exhibitions
Exhibition Life Science
Asia Pacific Societies for Extracellular Vesicles 2026, 22nd - 23rd October
The 13th Annual Meeting of the Japanese Society for Extracellular Vesicles (APSEV2026 / JSEV2026).
Outline
- Date
- 22nd - 23rd October, 2026
- Place
- JP TOWER Hall & Conference Tokyo, Japan
- Address
- 2-7-2 Marunouchi, Chiyoda-ku, Tokyo 100-0005, Japan
- Booth#
- 45
Poster Presentation
Poster Presentation 1
- Date & Time
- 1:00pm -2:00pm (JST), Friday, October 23rd, 2026
- Venue
- Conference B
- Poster No.
- AP-77
- Title
- Development of a method for large-scale purification of extracellular vesicles using the PS affinity method
- Presenter
- Takamasa Ishidome, Ph.D., Biotechnology Center, FUJIFILM Wako Pure Chemical Corporation
At APSEV 2026, FUJIFILM Wako will present our latest research on large-scale extracellular vesicle purification using the PS affinity method.
The study demonstrates how Tim4-based affinity purification enables high-purity and high-recovery EV isolation while preserving biological activity across different manufacturing scales. The technology offers a promising approach toward reproducible and scalable production of therapeutic EVs for research and future clinical applications.
Visit our poster to learn how PS affinity purification may help advance next-generation EV manufacturing workflows.
Poster Presentation 2
- Date & Time
- 1:00pm -2:00pm (JST), Friday, October 23rd, 2026
- Venue
- Conference B
- Poster No.
- AP-77
- Title
- Analysis of EV Marker Levels in Blood Samples from Patients with Neurodegenerative Diseases Using EV ELISA
- Presenter
- Naoko Imawaka, Biotechnology Center, FUJIFILM Wako Pure Chemical Corporation
FUJIFILM Wako will present our study analyzing extracellular vesicle (EV) marker levels in blood samples from patients with Alzheimer's disease (AD) and Parkinson's disease (PD) using EV ELISA.
Using two ELISA approaches, we observed lower CD9 levels in plasma from patients with AD and PD compared with healthy individuals. Single-particle analysis also showed that approximately 90% of platelet-marker-positive EVs co-expressed CD9, while levels of the platelet markers CD41 and CD61 also tended to be lower in patient samples. These findings suggest a potential reduction in platelet-derived EVs in the blood of patients with AD and PD.
Visit Poster JP-61 at Booth No. 45 to learn more about our findings and their potential relevance to EV research in neurodegenerative diseases. Scan for a chance to win a prize!